Market Research Logo

Small Molecule API Market:Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027

Small Molecule API Market:Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027

Global scenario of the small molecule API market – moderate growth rate observed

The global small molecule API market is anticipated to grow at a moderate rate to register a CAGR of 4.9% during the period of forecast, 2017-2027. There are several aspects that govern the growth rate of the global small molecule API market. The key drivers fuelling the growth of the market are factors such as rise in small molecule API growth, the HPAPI witnessing higher boost in growth rate, and the pharmerging countries being explored as alternative sourcing destinations. Trends such as the sourcing of the APIs done from Indian pharmaceutical manufacturers based in the U.S and higher investment in infrastructural facilities in order to raise the in-house production also contribute to the growth of the global small molecule API market. Moreover, owing to these drivers and trends, there are certain opportunities that lurk within the global small molecule API market. To name a few – the growth in healthcare spending in developing nations such as Asia Pacific and other regions and expansion with respect to product offerings as well as reduction in the costs involved.

Asia Pacific excluding Japan to grow at full speed and gain high market share

Asia Pacific excluding Japan (APEJ) reflects higher speed by registering a growth rate of 5.8% during the forecast period 2017 to 2025. The Asian countries hold significant revenue share in the entire market. Most of the anti-inflammatory drugs as well as antibiotic drugs are produced in the Asian counties, with China and India topping the list. Almost 80% of the total antibiotic APIs are produced in China and India and most of these APIs are outsourced to developed regions such as Europe and North America. The main reasons for this to be possible is the abundant availability of raw material needed to produce APIs, and the availability of low cost labour in India and China. Additionally, these regions enjoy a favourable regulatory assistance along with low taxation policies in order to establish API manufacturing businesses. Also, a large patient population consumes non-controlled drugs, which makes Asia Pacific excluding Japan experience a higher in-house API consumption. The APEJ region also reflects a high market attractiveness and higher market share of almost 34% estimated to be held in 2017. This percentage is expected to rise even higher by the end of 2027, following the major trends that push the growth of the global small molecule API market in the APEJ region.

The pharma companies in India had filed DMFs making India the leading country in DMF filing. This infers that in the near future, majority of the API manufacturing contracts from U.S. based companies would be awarded to India based companies. Moreover, the rapid rise in the Indian generics market will also fuel the API market growth in this region.The Asia Pacific excluding Japan region is all set to experience a tremendous growth rate during the forecast period. The APEJ small molecule API market is expected to show a high figure of more than US$ 52 Bn by the end of 2027 and dominate the global market. The main reason for this growth is the high outsourcing in this region. Developing nations of China and India lead by SMEs. The production in these countries is rising owing to limited regulatory coverage. Also, the in-house consumption in India is higher, which has resulted in increased focus on the manufacturing of APIs in India.

The distribution network is also extensive in the overseas markets especially in regions such as Europe, United States and South Africa. Another factor supporting the statement that APEJ is experiencing higher growth is – Indian companies manufacturing APIs are taking advantage of the export opportunities especially in the Latin America region. All these trends are aiding the facts that are favourable for the growth of the small molecule API market in the APEJ region. The region that is the most growing and anticipated to grow even further is China, which shows a higher growth rate to register a CAGR of 6.9% followed by India.


1. Executive Summary
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Small Molecule Active Pharmaceutical Ingredient Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Scenario
3.4. Pipeline Assessment
4. North America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Pestle Analysis
4.3. Regional Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends
4.4. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
4.4.1. U.S.
4.4.2. Canada
4.5. Market Size (US$ Mn) Forecast By Country, 2017–2027
4.5.1. U.S.
4.5.2. Canada
4.6. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
4.6.1. Standard API
4.6.2. High Potency API
4.7. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
4.7.1. Standard API
4.7.2. High Potency API
4.8. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
4.8.1. In-House
4.8.2. Outsourced
4.9. Market Size (US$ Mn) Forecast By Production, 2017–2027
4.9.1. In-House
4.9.2. Outsourced
4.10. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
4.10.1. Clinical
4.10.2. Commercial
4.11. Market Size (US$ Mn) Analysis By Application, 2017–2027
4.11.1. Clinical
4.11.2. Commercial
4.12. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
4.12.1. Cardiovascular
4.12.2. Respiratory
4.12.3. Infectious
4.12.4. Metabolic
4.12.5. Oncology
4.12.6. Immunology
4.12.7. Neurology
4.12.8. Urology
4.12.9. Dermatology
4.12.10. Ophthalmology
4.12.11. General Health
4.12.12. Others
4.13. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
4.13.1. Cardiovascular
4.13.2. Respiratory
4.13.3. Infectious
4.13.4. Metabolic
4.13.5. Oncology
4.13.6. Immunology
4.13.7. Neurology
4.13.8. Urology
4.13.9. Dermatology
4.13.10. Ophthalmology
4.13.11. General Health
4.13.12. Others
4.14. Drivers and Restraints: Impact Analysis
4.15. Market Attractiveness Analysis
4.15.1. By Country
4.15.2. By Molecule Type
4.15.3. By Production
4.15.4. By Application
4.15.5. By Therapeutic Area
4.16. Key Representative Market Participants
4.17. Market Presence (Intensity Map)
5. Latin America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
5.5.1. Standard API
5.5.2. High Potency API
5.6. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
5.6.1. Standard API
5.6.2. High Potency API
5.7. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
5.7.1. In-House
5.7.2. Outsourced
5.8. Market Size (US$ Mn) Forecast By Production, 2017–2027
5.8.1. In-House
5.8.2. Outsourced
5.9. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
5.9.1. Clinical
5.9.2. Commercial
5.10. Market Size (US$ Mn) Analysis By Application, 2017–2027
5.10.1. Clinical
5.10.2. Commercial
5.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
5.11.1. Cardiovascular
5.11.2. Respiratory
5.11.3. Infectious
5.11.4. Metabolic
5.11.5. Oncology
5.11.6. Immunology
5.11.7. Neurology
5.11.8. Urology
5.11.9. Dermatology
5.11.10. Ophthalmology
5.11.11. General Health
5.11.12. Others
5.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
5.12.1. Cardiovascular
5.12.2. Respiratory
5.12.3. Infectious
5.12.4. Metabolic
5.12.5. Oncology
5.12.6. Immunology
5.12.7. Neurology
5.12.8. Urology
5.12.9. Dermatology
5.12.10. Ophthalmology
5.12.11. General Health
5.12.12. Others
5.13. Drivers and Restraints: Impact Analysis
5.14. Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Molecule Type
5.14.3. By Production
5.14.4. By Application
5.14.5. By Therapeutic Area
5.15. Key Representative Market Participants
5.16. Market Presence (Intensity Map)
6. Western Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
6.3.1. Germany
6.3.2. Italy
6.3.3. France
6.3.4. Spain
6.3.5. U.K.
6.3.6. BENELUX
6.3.7. Nordic
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
6.4.1. Germany
6.4.2. Italy
6.4.3. France
6.4.4. Spain
6.4.5. U.K.
6.4.6. BENELUX
6.4.7. Nordic
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
6.5.1. Standard API
6.5.2. High Potency API
6.6. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
6.6.1. Standard API
6.6.2. High Potency API
6.7. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
6.7.1. In-House
6.7.2. Outsourced
6.8. Market Size (US$ Mn) Forecast By Production, 2017–2027
6.8.1. In-House
6.8.2. Outsourced
6.9. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
6.9.1. Clinical
6.9.2. Commercial
6.10. Market Size (US$ Mn) Analysis By Application, 2017–2027
6.10.1. Clinical
6.10.2. Commercial
6.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
6.11.1. Cardiovascular
6.11.2. Respiratory
6.11.3. Infectious
6.11.4. Metabolic
6.11.5. Oncology
6.11.6. Immunology
6.11.7. Neurology
6.11.8. Urology
6.11.9. Dermatology
6.11.10. Ophthalmology
6.11.11. General Health
6.11.12. Others
6.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
6.12.1. Cardiovascular
6.12.2. Respiratory
6.12.3. Infectious
6.12.4. Metabolic
6.12.5. Oncology
6.12.6. Immunology
6.12.7. Neurology
6.12.8. Urology
6.12.9. Dermatology
6.12.10. Ophthalmology
6.12.11. General Health
6.12.12. Others
6.13. Drivers and Restraints: Impact Analysis
6.14. Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Molecule Type
6.14.3. By Production
6.14.4. By Application
6.14.5. By Therapeutic Area
6.15. Key Representative Market Participants
6.16. Market Presence (Intensity Map)
7. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
7.2.1. Russia
7.2.2. Poland
7.2.3. Rest of Eastern Europe
7.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
7.4.1. Standard API
7.4.2. High Potency API
7.5. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
7.5.1. Standard API
7.5.2. High Potency API
7.6. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
7.6.1. In-House
7.6.2. Outsourced
7.7. Market Size (US$ Mn) Forecast By Production, 2017–2027
7.7.1. In-House
7.7.2. Outsourced
7.8. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
7.8.1. Clinical
7.8.2. Commercial
7.9. Market Size (US$ Mn) Analysis By Application, 2017–2027
7.9.1. Clinical
7.9.2. Commercial
7.10. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
7.10.1. Cardiovascular
7.10.2. Respiratory
7.10.3. Infectious
7.10.4. Metabolic
7.10.5. Oncology
7.10.6. Immunology
7.10.7. Neurology
7.10.8. Urology
7.10.9. Dermatology
7.10.10. Ophthalmology
7.10.11. General Health
7.10.12. Others
7.11. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
7.11.1. Cardiovascular
7.11.2. Respiratory
7.11.3. Infectious
7.11.4. Metabolic
7.11.5. Oncology
7.11.6. Immunology
7.11.7. Neurology
7.11.8. Urology
7.11.9. Dermatology
7.11.10. Ophthalmology
7.11.11. General Health
7.11.12. Others
7.12. Drivers and Restraints: Impact Analysis
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Molecule Type
7.13.3. By Production
7.13.4. By Application
7.13.5. By Therapeutic Area
7.14. Key Representative Market Participants
7.15. Market Presence (Intensity Map)
8. Asia Pacific excluding Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
8.3.1. China
8.3.2. India
8.3.3. ASEAN
8.3.4. Australia and New Zealand
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
8.4.1. China
8.4.2. India
8.4.3. ASEAN
8.4.4. Australia and New Zealand
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
8.5.1. Standard API
8.5.2. High Potency API
8.6. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
8.6.1. Standard API
8.6.2. High Potency API
8.7. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
8.7.1. In-House
8.7.2. Outsourced
8.8. Market Size (US$ Mn) Forecast By Production, 2017–2027
8.8.1. In-House
8.8.2. Outsourced
8.9. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
8.9.1. Clinical
8.9.2. Commercial
8.10. Market Size (US$ Mn) Analysis By Application, 2017–2027
8.10.1. Clinical
8.10.2. Commercial
8.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
8.11.1. Cardiovascular
8.11.2. Respiratory
8.11.3. Infectious
8.11.4. Metabolic
8.11.5. Oncology
8.11.6. Immunology
8.11.7. Neurology
8.11.8. Urology
8.11.9. Dermatology
8.11.10. Ophthalmology
8.11.11. General Health
8.11.12. Others
8.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
8.12.1. Cardiovascular
8.12.2. Respiratory
8.12.3. Infectious
8.12.4. Metabolic
8.12.5. Oncology
8.12.6. Immunology
8.12.7. Neurology
8.12.8. Urology
8.12.9. Dermatology
8.12.10. Ophthalmology
8.12.11. General Health
8.12.12. Others
8.13. Drivers and Restraints: Impact Analysis
8.14. Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Molecule Type
8.14.3. By Production
8.14.4. By Application
8.14.5. By Therapeutic Area
8.15. Key Representative Market Participants
8.16. Market Presence (Intensity Map)
9. Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
9.2.1. Standard API
9.2.2. High Potency API
9.3. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
9.3.1. Standard API
9.3.2. High Potency API
9.4. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
9.4.1. In-House
9.4.2. Outsourced
9.5. Market Size (US$ Mn) Forecast By Production, 2017–2027
9.5.1. In-House
9.5.2. Outsourced
9.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
9.6.1. Clinical
9.6.2. Commercial
9.7. Market Size (US$ Mn) Analysis By Application, 2017–2027
9.7.1. Clinical
9.7.2. Commercial
9.8. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
9.8.1. Cardiovascular
9.8.2. Respiratory
9.8.3. Infectious
9.8.4. Metabolic
9.8.5. Oncology
9.8.6. Immunology
9.8.7. Neurology
9.8.8. Urology
9.8.9. Dermatology
9.8.10. Ophthalmology
9.8.11. General Health
9.8.12. Others
9.9. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
9.9.1. Cardiovascular
9.9.2. Respiratory
9.9.3. Infectious
9.9.4. Metabolic
9.9.5. Oncology
9.9.6. Immunology
9.9.7. Neurology
9.9.8. Urology
9.9.9. Dermatology
9.9.10. Ophthalmology
9.9.11. General Health
9.9.12. Others
9.10. Drivers and Restraints: Impact Analysis
9.11. Market Attractiveness Analysis
9.11.1. By Molecule Type
9.11.2. By Production
9.11.3. By Application
9.11.4. By Therapeutic Area
9.12. Key Representative Market Participants
9.13. Market Presence (Intensity Map)
10. Middle East & Africa Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
10.2.1. GCC Countries
10.2.2. Turkey
10.2.3. Northern Africa
10.2.4. South Africa
10.2.5. Rest of MEA
10.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
10.3.1. GCC Countries
10.3.2. Turkey
10.3.3. Northern Africa
10.3.4. South Africa
10.3.5. Rest of MEA
10.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
10.4.1. Standard API
10.4.2. High Potency API
10.5. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
10.5.1. Standard API
10.5.2. High Potency API
10.6. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
10.6.1. In-House
10.6.2. Outsourced
10.7. Market Size (US$ Mn) Forecast By Production, 2017–2027
10.7.1. In-House
10.7.2. Outsourced
10.8. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
10.8.1. Clinical
10.8.2. Commercial
10.9. Market Size (US$ Mn) Analysis By Application, 2017–2027
10.9.1. Clinical
10.9.2. Commercial
10.10. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
10.10.1. Cardiovascular
10.10.2. Respiratory
10.10.3. Infectious
10.10.4. Metabolic
10.10.5. Oncology
10.10.6. Immunology
10.10.7. Neurology
10.10.8. Urology
10.10.9. Dermatology
10.10.10. Ophthalmology
10.10.11. General Health
10.10.12. Others
10.11. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
10.11.1. Cardiovascular
10.11.2. Respiratory
10.11.3. Infectious
10.11.4. Metabolic
10.11.5. Oncology
10.11.6. Immunology
10.11.7. Neurology
10.11.8. Urology
10.11.9. Dermatology
10.11.10. Ophthalmology
10.11.11. General Health
10.11.12. Others
10.12. Drivers and Restraints: Impact Analysis
10.13. Market Attractiveness Analysis
10.13.1. By Country
10.13.2. By Molecule Type
10.13.3. By Production
10.13.4. By Application
10.13.5. By Therapeutic Area
10.14. Key Representative Market Participants
10.15. Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Market Structure
13.2. Competition Dashboard
13.3. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
13.3.1. Johnson Matthey
13.3.2. Siegfried Holding AG
13.3.3. Pfizer
13.3.4. Sanofi S.A.
13.3.5. Novartis AG,
13.3.6. Bristol-Myers Squibb,
13.3.7. Boehringer Ingelheim GmbH
13.3.8. GlaxoSmithKline PLC, GILEAD Science Inc.,
13.3.9. Albany Molecular Research Inc.
13.3.10. Bachem Holding AG
13.3.11. PCAS
13.3.12. Patheon N.V.
13.3.13. AstraZeneca
13.3.14. Johnson & Johnson
13.3.15. Merck & Co, Inc.
13.3.16. BASF SE
13.3.17. Catalent Inc.
13.3.18. Teva Pharmaceuticals
13.3.19. F. Hoffmann-La Roche Ltd
13.3.20. Cambrex Corporation
13.3.21. GILEAD Science Inc.
14. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2012–2016
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific excluding Japan
14.2.6. Japan
14.2.7. Middle East & Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2017–2027
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific excluding Japan
14.3.6. Japan
14.3.7. Middle East & Africa
14.4. Market Attractiveness Analysis By Region
15. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
15.2.1. Standard API
15.2.2. High Potency API
15.3. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
15.3.1. Standard API
15.3.2. High Potency API
15.4. Market Attractiveness Analysis By Molecule Type
16. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Production
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
16.2.1. In-House
16.2.2. Outsourced
16.3. Market Size (US$ Mn) Forecast By Production, 2017–2027
16.3.1. In-House
16.3.2. Outsourced
16.4. Market Attractiveness Analysis By Application
17. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Application
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
17.2.1. Clinical
17.2.2. Commercial
17.3. Market Size (US$ Mn) Analysis By Application, 2017–2027
17.3.1. Clinical
17.3.2. Commercial
17.4. Market Attractiveness Analysis By Application
18. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Therapeutic Area
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
18.2.1. Cardiovascular
18.2.2. Respiratory
18.2.3. Infectious
18.2.4. Metabolic
18.2.5. Oncology
18.2.6. Immunology
18.2.7. Neurology
18.2.8. Urology
18.2.9. Dermatology
18.2.10. Ophthalmology
18.2.11. General Health
18.2.12. Others
18.3. Market Size (US$ Mn) Analysis By Therapeutic Area, 2017–2027
18.3.1. Cardiovascular
18.3.2. Respiratory
18.3.3. Infectious
18.3.4. Metabolic
18.3.5. Oncology
18.3.6. Immunology
18.3.7. Neurology
18.3.8. Urology
18.3.9. Dermatology
18.3.10. Ophthalmology
18.3.11. General Health
18.3.12. Others
18.4. Market Attractiveness Analysis By Therapeutic Area
19. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report